{"nctId":"NCT03027557","briefTitle":"Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.","startDateStruct":{"date":"2017-03-01","type":"ACTUAL"},"conditions":["Primary Hyperparathyroidism","Parathyroid Adenoma","Parathyroid Hyperplasia"],"count":46,"armGroups":[{"label":"Combined treatment.","type":"EXPERIMENTAL","interventionNames":["Drug: Cinacalcet 30 mg Tablet","Drug: Denosumab Inj 60 mg/ml"]},{"label":"Monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Denosumab Inj 60 mg/ml","Other: Placebo tablets"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo tablets","Other: Saline Injection (Placebo)"]}],"interventions":[{"name":"Cinacalcet 30 mg Tablet","otherNames":["Mimpara","Sensipar"]},{"name":"Denosumab Inj 60 mg/ml","otherNames":["Prolia","Xgeva"]},{"name":"Placebo tablets","otherNames":[]},{"name":"Saline Injection (Placebo)","otherNames":["Sodium Chloride (NaCl) Fresenius \"Kabi\""]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women of 18 years of age or older.\n* T-score by Dual X-ray Absorptiometry (DXA) between -1,0 og -3,5\n* Patients from The North Jutland Region diagnosed with primary hyperparathyroidism at the Department of Endocrinology, Aalborg University Hospital. (Hypercalcaemia measured at two different time-points and simultaneous elevated/inappropriately high PTH, and exclusion of differential diagnosis.)\n\nExclusion Criteria:\n\n* Medical history of diseases leading to hypercalcaemia other than Primary Hyperparathyroidism.\n* Patients being treated with Denosumab or Cinacalcet prior to inclusion or previously treated with Denosumab or Cinacalcet.\n* Moderately - Severely decreased liver function (alanine aminotransferase \\>250u/l, gamma-glutamyl transferase\\>150u/l, Bilirubin \\>30)\n* Acute myocardial infarction or apoplexia in the 3 months before inclusion.\n* Medical record of heart failure\n* Risk factors of prolonged corrected QT interval (QTc).\n* Open lesions from oral surgery.\n* Primary diseases of the bone other than osteoporosis.\n* Patients suffering from kidney disease or renal failure.\n* Patients under treatment with thiazide or lithium.\n* Medical record of generalized seizures or epilepsy.\n* Active malignant disease.\n* Known allergies towards the specified medicinal products (IMPs).\n* Pregnancy or breastfeeding.\n* Fertile women who do not agree to the usage of effective contraception.\n* Other circumstances, evaluated by the responsible investigator, making the subject unsuitable for participation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Lumbar Spine Bone Mineral Density","description":"Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.030","spread":"0.009"},{"groupId":"OG001","value":"0.042","spread":"0.009"},{"groupId":"OG002","value":"-0.016","spread":"0.007"}]}]}]},{"type":"PRIMARY","title":"Change in Total Hip Bone Mineral Density","description":"Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":"0.006"},{"groupId":"OG001","value":"0.021","spread":"0.003"},{"groupId":"OG002","value":"-0.013","spread":"0.006"}]}]}]},{"type":"PRIMARY","title":"Change in Femoral Neck Bone Mineral Density","description":"Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.006"},{"groupId":"OG001","value":"0.020","spread":"0.005"},{"groupId":"OG002","value":"-0.007","spread":"0.006"}]}]}]},{"type":"PRIMARY","title":"Change in 1/3 Forearm Bone Mineral Density","description":"Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.005","spread":"0.003"},{"groupId":"OG001","value":"0.005","spread":"0.003"},{"groupId":"OG002","value":"-0.005","spread":"0.004"}]}]}]},{"type":"PRIMARY","title":"Percentage Change in Lumbar Spine Bone Mineral Density","description":"Percentage change of Bone Mineral Density after one year of treatment from baseline.\n\nMeasured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.1"},{"groupId":"OG001","value":"5.1","spread":"1.1"},{"groupId":"OG002","value":"-1.8","spread":"0.8"}]}]}]},{"type":"PRIMARY","title":"Percentage Change in Total Hip Bone Mineral Density","description":"Percentage change of Bone Mineral Density after one year of treatment from baseline.\n\nMeasured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":"0.72"},{"groupId":"OG001","value":"2.64","spread":"0.41"},{"groupId":"OG002","value":"-1.50","spread":"0.72"}]}]}]},{"type":"PRIMARY","title":"Percentage Change in Femoral Neck Bone Mineral Density","description":"Percentage change of Bone Mineral Density after one year of treatment from baseline.\n\nMeasured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"0.98"},{"groupId":"OG001","value":"3.03","spread":"0.86"},{"groupId":"OG002","value":"-0.78","spread":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage Change in 1/3 Forearm Bone Mineral Density","description":"Percentage change of Bone Mineral Density after one year of treatment from baseline.\n\nMeasured with Dual-energy X-ray absorptiometry (DXA)-scan.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"0.7"},{"groupId":"OG001","value":"0.88","spread":"0.5"},{"groupId":"OG002","value":"-0.91","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change in Volumetric BMD for the Lumbar Spine.","description":"Measured at baseline and after one year by QCT.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","spread":"2.15"},{"groupId":"OG001","value":"5.35","spread":"1.91"},{"groupId":"OG002","value":"-2.56","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Mean P-calcium During Treatment.","description":"Blood samples were acquired once every 4 weeks for safety-purposes.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"0.007"},{"groupId":"OG001","value":"1.38","spread":"0.006"},{"groupId":"OG002","value":"1.40","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in P-carboxy-terminal Collagen Crosslinks (CTX)","description":"p-CTX, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.7","spread":null},{"groupId":"OG001","value":"-58.2","spread":null},{"groupId":"OG002","value":"11.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Agatstons Score Final","description":"Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, \\>400 severe calcification.\n\nThus the score increases with increasing level of calcification in the coronary vessels.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"24.3","spread":null},{"groupId":"OG002","value":"117.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Nephrolithiasis Final Scan.","description":"Number of subjects w. renal stones at final scan.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Pancreas-calcifications Final Scan.","description":"By QCT.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Reset of the Calcium Sensing Receptor?","description":"Measured from effect on s-calcium and PTH weeks after termination of IMP","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Vertebral Fracture Assessment - Final Scan","description":"Number of participants with vertebral fractures as assessed by VFA at final scan.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change MDI-score","description":"Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported.\n\nThe Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Reactions.","description":"All participants filled in questionnaires regarding symptoms related to the treatment.\n\nResults are reported in the Adverse Events section.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Bone Mineral Content","description":"Measured at baseline and after one year at the lumbar spine and distal 1/3 of the non-dominant antebrachii.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Cortical Width.","description":"Measured at baseline and after one year at the distal non-dominant antebrachii.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.1"},{"groupId":"OG001","value":"0.02","spread":"0.08"},{"groupId":"OG002","value":"0.04","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Volumetric BMD for the Distal Forearm.","description":"Measured at baseline and after one year by QCT.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"2.1"},{"groupId":"OG001","value":"9.6","spread":"3.7"},{"groupId":"OG002","value":"-1.1","spread":"4.6"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Volumetric BMD for the Lumbar Spine.","description":"Measured at baseline and after one year by QCT.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.18","spread":"3.14"},{"groupId":"OG001","value":"5.66","spread":"1.85"},{"groupId":"OG002","value":"-2.94","spread":"1.96"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Volumetric BMD for the Distal Forearm.","description":"Measured at baseline and after one year by QCT.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"1.2"},{"groupId":"OG001","value":"5.2","spread":"1.0"},{"groupId":"OG002","value":"-0.74","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Mean p-PTH During Treatment.","description":"Blood samples were acquired once every 4 weeks for safety-purposes.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"13.4","spread":null},{"groupId":"OG002","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean p-Phosphate During Treatment.","description":"Blood samples were acquired once every 4 weeks for safety-purposes.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.013"},{"groupId":"OG001","value":"0.76","spread":"0.012"},{"groupId":"OG002","value":"0.083","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in p-N-terminal Propeptide of Type I Procollagen (p-P1NP).","description":"p-P1NP, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.1","spread":null},{"groupId":"OG001","value":"-66.1","spread":null},{"groupId":"OG002","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in P-osteocalcin.","description":"p-osteocalcin, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.0","spread":null},{"groupId":"OG001","value":"-58.9","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in S-bone-specific Alkaline Phosphatase (BAP).","description":"S-Bone specific alkaline phosphatase, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.0","spread":null},{"groupId":"OG001","value":"-46.3","spread":null},{"groupId":"OG002","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).","description":"P-Trap5b, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.8","spread":null},{"groupId":"OG001","value":"-36.7","spread":null},{"groupId":"OG002","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in p-Sclerostin.","description":"P-Sclerostin, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).","description":"P-FGF23 , change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"20.4","spread":null},{"groupId":"OG002","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in p-25-vitamin D","description":"P-25-vitD , change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"16.0","spread":null},{"groupId":"OG002","value":"21.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in s-1,25-vitamin D","description":"S-1,25-vitD, change from baseline at 48 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"26.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Nephrocalcinosis, Final Scan.","description":"Number of subjects w. renal calcifications at final scan.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Safety Measures","description":"Biochemical measures of changes in liver, infection, kidney and electrolyte-status and urinary excretion of calcium.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":15},"commonTop":["Nausea","Musculoskeletal pain","Upper respiratory tract infection","Paraesthesia, hands","Paraesthesia, feet"]}}}